Marwa S. A. Hassan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marwa S. A. Hassan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Eman M. Ahmed
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Cairo University Cairo Egypt
4 shared publicationsNadia A. Khalil
Pharmaceutical Organic Chemistry Department Faculty of Pharmacy Cairo University Cairo Egypt
2 shared publicationsSara Y. Ewieda
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Egypt
2 shared publications- Amira A. Helwa
Pharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing Misr University for Science and Technology (MUST) 6th of October City Egypt
1 shared publication Amr K. A. Bass
Pharmaceutical Chemistry Department Faculty of Pharmacy Menoufia University Menoufia Egypt
1 shared publicationAmr M. Abdou
Department of Microbiology and Immunology, National Research Centre, Dokki, Giza 12622, Egypt
1 shared publication
Latest Publications
- 4 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10) , e70349
Pyridine and Fused Pyridine Derivatives as Selective COX‐2 Inhibitors: A Comprehensive Review of Synthetic Pathways, Anti‐Inflammatory, and Antinociceptive Activities
Selective cyclooxygenase‐2 inhibitors (COXIBs) are preferred over traditional nonsteroidal anti‐inflammatory drugs (NSAIDs) owing to their improved gastrointestinal and renal safety profile. Pyridine is one of the most important nitrogen‐containing heterocyclic scaffolds, and it is present in the structures of more than 7000 marketed drugs and biologically active compounds. Among these are anti‐inflammatory agents, including the selective cyclooxygenase‐2 (COX‐2) inhibitors niflumic acid and etoricoxib. This review highlights the synthetic approaches to pyridine and fused pyridine derivatives, covering 42 published studies on pyridine synthesis, and critically evaluates 40 published studies on pyridine‐containing scaffolds exhibiting COX‐2 inhibitory activity. Several pyridine derivatives demonstrated potent COX‐2 inhibitory activity, with reported IC 50 values ranging from the nanomolar to micromolar level. Analysis of these studies revealed that 17 of the 40 studies reported compounds that exhibited superior COX‐2 inhibitory activity than the reference drugs evaluated under the same experimental conditions. Among these 17 studies, 6 involved fused pyridine scaffolds. These findings support the pyridine scaffold as a promising platform for the development of selective COX‐2 inhibitors. Therefore, this review provides a valuable resource for guiding the rational design and development of novel selective COX‐2 inhibitors.
- 4 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10) , e70349
Pyridine and Fused Pyridine Derivatives as Selective COX‐2 Inhibitors: A Comprehensive Review of Synthetic Pathways, Anti‐Inflammatory, and Antinociceptive Activities
Selective cyclooxygenase‐2 inhibitors (COXIBs) are preferred over traditional nonsteroidal anti‐inflammatory drugs (NSAIDs) owing to their improved gastrointestinal and renal safety profile. Pyridine is one of the most important nitrogen‐containing heterocyclic scaffolds, and it is present in the structures of more than 7000 marketed drugs and biologically active compounds. Among these are anti‐inflammatory agents, including the selective cyclooxygenase‐2 (COX‐2) inhibitors niflumic acid and etoricoxib. This review highlights the synthetic approaches to pyridine and fused pyridine derivatives, covering 42 published studies on pyridine synthesis, and critically evaluates 40 published studies on pyridine‐containing scaffolds exhibiting COX‐2 inhibitory activity. Several pyridine derivatives demonstrated potent COX‐2 inhibitory activity, with reported IC 50 values ranging from the nanomolar to micromolar level. Analysis of these studies revealed that 17 of the 40 studies reported compounds that exhibited superior COX‐2 inhibitory activity than the reference drugs evaluated under the same experimental conditions. Among these 17 studies, 6 involved fused pyridine scaffolds. These findings support the pyridine scaffold as a promising platform for the development of selective COX‐2 inhibitors. Therefore, this review provides a valuable resource for guiding the rational design and development of novel selective COX‐2 inhibitors.
- 10 August 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (8) , e70061
From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy
Pyrazole derivatives have emerged as versatile scaffolds in the development of receptor tyrosine kinase inhibitors, offering promising avenues for targeted cancer therapy. Their therapeutic potential in cancer therapy is notable in many FDA‐approved anticancer drugs. This review provides a comprehensive overview of the latest research from 2021 regarding novel pyrazole, pyrazoline, and fused pyrazole derivatives targeting receptor tyrosine kinases, namely: AXL, DDR, EGFR, FGFR, MET, CSF1R, RET, and VEGFR‐2. This study focuses on the most active and promising candidates within each series of compounds. Key aspects covered include their cytotoxicity and enzyme inhibition results, with comparisons to reference drugs. The review also covers the molecular docking studies, highlighting critical binding interactions between the compounds and the protein kinase residues, and unveiling their molecular mechanisms of action. Structure–activity relationship analyses are also discussed, revealing the influence of structural modifications on biological activities. Furthermore, synthetic pathways for each series or key compounds are presented, offering a practical guide for researchers in the field. By integrating these elements, this review provides a solid foundation and rationale for the design, synthesis, and optimization of new pyrazole‐based anticancer agents targeting receptor tyrosine kinases.
- 10 August 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (8) , e70061
From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy
Pyrazole derivatives have emerged as versatile scaffolds in the development of receptor tyrosine kinase inhibitors, offering promising avenues for targeted cancer therapy. Their therapeutic potential in cancer therapy is notable in many FDA‐approved anticancer drugs. This review provides a comprehensive overview of the latest research from 2021 regarding novel pyrazole, pyrazoline, and fused pyrazole derivatives targeting receptor tyrosine kinases, namely: AXL, DDR, EGFR, FGFR, MET, CSF1R, RET, and VEGFR‐2. This study focuses on the most active and promising candidates within each series of compounds. Key aspects covered include their cytotoxicity and enzyme inhibition results, with comparisons to reference drugs. The review also covers the molecular docking studies, highlighting critical binding interactions between the compounds and the protein kinase residues, and unveiling their molecular mechanisms of action. Structure–activity relationship analyses are also discussed, revealing the influence of structural modifications on biological activities. Furthermore, synthetic pathways for each series or key compounds are presented, offering a practical guide for researchers in the field. By integrating these elements, this review provides a solid foundation and rationale for the design, synthesis, and optimization of new pyrazole‐based anticancer agents targeting receptor tyrosine kinases.
- 5 February 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (1) , e70056
Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives
The anticancer potential of certain newly synthesized pyrazole and pyrazolopyridine derivatives has been estimated. NCI 60 cancer cells cytotoxic screening pointed out compounds 3e and 3f as the highest cytotoxic agents with % mean growth inhibition of 67.69% and 87.34%, respectively. The five dose outcomes outlined 3f as the most potent cytotoxic agent with promising MG‐MID GI50 = 3.3 µM when compared to erlotinib (MG‐MID GI50 = 7.68 µM). In the in vitro assays, compounds 3d, 3e, 3f, and 4a demonstrated dual inhibitory potential on EGFRWT and VEGFR‐2 with IC50 range of 0.066−0.184 µM and 0.102−0.418 µM, respectively. The best dual EGFR/VEGRF‐2 inhibitory effect was shown by the compound 3f. Moreover, the latter compound stopped the cell cycle at the G1/S phase. Also, it greatly boosted total apoptosis, including early and late apoptosis, by 54.5‐ and 84.7‐fold, respectively, which supposes HCT‐116 cell death via inducing apoptosis. This was confirmed by the elevation of the BAX and caspase‐3 levels, and the decreased BCL‐2 level. Moreover, the safety of the most active compound 3f was assessed and the results showed promising selectivity of compound 3f toward HCT‐116 over FHC (selectivity index [SI]: 20.84) when compared to erlotinib (SI: 3.42). Finally, compound 3f demonstrated efficient binding to both EGFR and VEGFR‐2 enzymes, which could explain the sufficient inhibition level of each enzyme.
- 5 February 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (1) , e70056
Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives
The anticancer potential of certain newly synthesized pyrazole and pyrazolopyridine derivatives has been estimated. NCI 60 cancer cells cytotoxic screening pointed out compounds 3e and 3f as the highest cytotoxic agents with % mean growth inhibition of 67.69% and 87.34%, respectively. The five dose outcomes outlined 3f as the most potent cytotoxic agent with promising MG‐MID GI50 = 3.3 µM when compared to erlotinib (MG‐MID GI50 = 7.68 µM). In the in vitro assays, compounds 3d, 3e, 3f, and 4a demonstrated dual inhibitory potential on EGFRWT and VEGFR‐2 with IC50 range of 0.066−0.184 µM and 0.102−0.418 µM, respectively. The best dual EGFR/VEGRF‐2 inhibitory effect was shown by the compound 3f. Moreover, the latter compound stopped the cell cycle at the G1/S phase. Also, it greatly boosted total apoptosis, including early and late apoptosis, by 54.5‐ and 84.7‐fold, respectively, which supposes HCT‐116 cell death via inducing apoptosis. This was confirmed by the elevation of the BAX and caspase‐3 levels, and the decreased BCL‐2 level. Moreover, the safety of the most active compound 3f was assessed and the results showed promising selectivity of compound 3f toward HCT‐116 over FHC (selectivity index [SI]: 20.84) when compared to erlotinib (SI: 3.42). Finally, compound 3f demonstrated efficient binding to both EGFR and VEGFR‐2 enzymes, which could explain the sufficient inhibition level of each enzyme.
- 9 July 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 150, 107623
Synthesis, COX-2 inhibition, anti-inflammatory activity, molecular docking, and histopathological studies of new pyridazine derivatives
- 9 July 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 150, 107623
Synthesis, COX-2 inhibition, anti-inflammatory activity, molecular docking, and histopathological studies of new pyridazine derivatives
- 4 October 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (12) , e2300250
Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity
This study comprises the design and synthesis of novel nicotinic acid‐based cytotoxic agents with selective inhibitory efficacy against the vascular endothelial growth factor receptor‐2 (VEGFR‐2). Screening of novel compounds for cytotoxicity was assessed against 60 human cancer cell lines. The two most active compounds, 5b and 5c, and the reference drugs sorafenib and doxorubicin were investigated against HCT‐15, PC‐3, and CF‐295 cancer cell lines. Compound 5c exhibited the highest cytotoxic potential compared to doxorubicin against the HCT‐15 and PC‐3 tumor cell lines. Moreover, it exhibited higher cytotoxic potential and selectivity toward the HCT‐15 cell panel compared with sorafenib. Compound 5c demonstrated promising VEGFR‐2 inhibition (concentration needed to inhibit cell viability by 50%, IC50 = 0.068 μM) and superior VEGFR‐2 selectivity over the epidermal growth factor receptor and platelet‐derived growth factor receptor‐β enzymes. It also reduced the total and phosphorylated VEGFR‐2 and induced apoptosis, as evidenced by a 4.3‐fold rise in caspase‐3 levels. The antioxidant potential of the new compounds was determined via measuring the superoxide dismutase (SOD) levels, among which compound 5c exhibited an SOD level almost comparable to ascorbic acid. These results suggested that compound 5c exhibited dual cytotoxic and antioxidant activities. Docking of 5c into the VEGFR‐2 pocket showed a similar binding mode to sorafenib. Moreover, the ADME (absorption, distribution, metabolism, and excretion) profile of 5c outlined drug‐likeness. Finally, The density functional theory calculations displayed an increased binding affinity of 5c to the target enzyme.
- 4 October 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (12) , e2300250
Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity
This study comprises the design and synthesis of novel nicotinic acid‐based cytotoxic agents with selective inhibitory efficacy against the vascular endothelial growth factor receptor‐2 (VEGFR‐2). Screening of novel compounds for cytotoxicity was assessed against 60 human cancer cell lines. The two most active compounds, 5b and 5c, and the reference drugs sorafenib and doxorubicin were investigated against HCT‐15, PC‐3, and CF‐295 cancer cell lines. Compound 5c exhibited the highest cytotoxic potential compared to doxorubicin against the HCT‐15 and PC‐3 tumor cell lines. Moreover, it exhibited higher cytotoxic potential and selectivity toward the HCT‐15 cell panel compared with sorafenib. Compound 5c demonstrated promising VEGFR‐2 inhibition (concentration needed to inhibit cell viability by 50%, IC50 = 0.068 μM) and superior VEGFR‐2 selectivity over the epidermal growth factor receptor and platelet‐derived growth factor receptor‐β enzymes. It also reduced the total and phosphorylated VEGFR‐2 and induced apoptosis, as evidenced by a 4.3‐fold rise in caspase‐3 levels. The antioxidant potential of the new compounds was determined via measuring the superoxide dismutase (SOD) levels, among which compound 5c exhibited an SOD level almost comparable to ascorbic acid. These results suggested that compound 5c exhibited dual cytotoxic and antioxidant activities. Docking of 5c into the VEGFR‐2 pocket showed a similar binding mode to sorafenib. Moreover, the ADME (absorption, distribution, metabolism, and excretion) profile of 5c outlined drug‐likeness. Finally, The density functional theory calculations displayed an increased binding affinity of 5c to the target enzyme.
- 26 September 2023
- Published by Wiley in Drug Development Research
- Vol. 84 (8) , 1595-1623
Pyridazine derivatives as selective COX‐2 inhibitors: A review on recent updates
Selective cyclooxygenase (COX)‐2 inhibitors have several advantages over nonselective COX inhibitors (nonsteroidal anti‐inflammatory drugs [NSAIDs]), including the absence of adverse effects (renal and hepatic disorders) associated with the long‐term use of standard NSAIDs, as well as an improved gastrointestinal profile. The pyridazine nucleus is regarded as a promising scaffold for the development of powerful COX‐2 inhibitors, particularly when selectively functionalized. This article summarizes some methods for the synthesis of pyridazine derivatives. Furthermore, it covers all of the pyridazine derivatives that have appeared as selective COX‐2 inhibitors, making it useful as a reference for the rational design of novel selective COX‐2 inhibitors.
- 26 September 2023
- Published by Wiley in Drug Development Research
- Vol. 84 (8) , 1595-1623
Pyridazine derivatives as selective COX‐2 inhibitors: A review on recent updates
Selective cyclooxygenase (COX)‐2 inhibitors have several advantages over nonselective COX inhibitors (nonsteroidal anti‐inflammatory drugs [NSAIDs]), including the absence of adverse effects (renal and hepatic disorders) associated with the long‐term use of standard NSAIDs, as well as an improved gastrointestinal profile. The pyridazine nucleus is regarded as a promising scaffold for the development of powerful COX‐2 inhibitors, particularly when selectively functionalized. This article summarizes some methods for the synthesis of pyridazine derivatives. Furthermore, it covers all of the pyridazine derivatives that have appeared as selective COX‐2 inhibitors, making it useful as a reference for the rational design of novel selective COX‐2 inhibitors.